At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 30 target
Drug / intervention
KN026drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2-positive Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd·interventional·Posted May 11, 2021·Updated Jun 22, 2022
In Brief
A Phase 2 clinical trial evaluating KN026 for Breast Cancer. Targeting 30 participants across 1 site.
Detailed Summary
This is an open-lable, multicenter, and single arm phase II trial to evaluate treatment with KN026 plus docetaxel as neoadjuvant therapy in patients with early-stage (T1c or 2, N1, M0; T2 or 3, N0, M0) or locally advanced (T1c or 2 or 3, N2, M0; T3N1M0; T1c or 2 or 3, N3a or 3b, M0) HER2-positive breast cancer. The subjects will receive KN026 30 mg/kg IV + Docetaxel 75/m2 every 3 weeks for four cycles prior to surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20222023202420252026
First PostedMay 2021
Enrollment StartAug 2021
Primary CompletionNov 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedMay 11, 2021
Enrollment StartAug 9, 2021
Primary CompletionNov 15, 2022
Study CompletionFeb 15, 2023
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 5.1 years ago
Interventions
KN026drug
KN026 in Combination With Docetaxel